埃罗替尼靶向治疗非小细胞肺癌的效果及对患者免疫功能及生存时间的影响分析  

Effect analysis of erlotinib targeted therapy on non-small cell lung cancer and its influence on immune function and survival time of patients

作　　者：梁胜涛 易素平 马志伟 LIANG Sheng-tao;YI Su-ping;MA Zhi-wei(Dachang Hospital of Baoshan District,Shanghai 200444,China)

机构地区：[1]上海市宝山区大场医院(上海交通大学医学院附属仁济医院宝山分院),200444 [2]上海交通大学医学院附属仁济医院肿瘤介入科,200127 [3]上海宝山仁和医院,200431

出　　处：《中国实用医药》2022年第6期142-144,共3页China Practical Medicine

摘　　要：目的分析埃罗替尼靶向治疗非小细胞肺癌的效果及对患者免疫功能及生存时间的影响。方法112例非小细胞肺癌患者,采取随机数字表法分为对照组和观察组,各56例。对照组采取吉他西滨+顺铂(GP)化疗方案治疗,观察组在对照组基础上应用埃罗替尼靶向治疗。比较两组患者治疗前后免疫功能及生存时间。结果治疗前,两组患者CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)对比,差异无统计学意义(P>0.05);治疗后,观察组患者CD4^(+)(0.52±0.07)%、CD4^(+)/CD8^(+)(1.70±0.23)明显高于对照组的(0.45±0.06)、(1.38±0.26),CD8^(+)(0.23±0.02)明显低于对照组的(0.32±0.04),差异有统计学意义(P<0.05)。观察组患者治疗后3个月、6个月、1年的生存率分别为100.00%、98.21%、94.64%,明显高于对照组的92.86%、87.50%、80.36%,差异有统计学意义(P<0.05)。结论应用埃罗替尼靶向治疗非小细胞肺癌可改善患者免疫功能,延长患者生存时间,值得推广。Objective To analyze the effect of erlotinib targeted therapy on non-small cell lung cancer and its influence on immune function and survival time of patients.Methods A total of 112 patients with nonsmall cell lung cancer were randomly divided into control group and observation group by random numerical table,with 56 cases in each group.The control group was treated with gemcitabine+cisplatin(GP)chemotherapy,and the observation group was treated with erlotinib targeted therapy on the basis of the control group.The immune function before and after treatment and survival time of the two groups were compared.Results Before treatment,there was no statistically significant difference in CD4^(+),CD8^(+),CD4^(+)/CD8^(+)between the two groups(P>0.05).After treatment,the CD4^(+)(0.52±0.07)%and CD4^(+)/CD8^(+)(1.70±0.23)of the observation group were significantly higher than(0.45±0.06)and(1.38±0.26)of the control group,and the CD8^(+)(0.23±0.02)was significantly lower than(0.32±0.04)of the control group.All the differences were statistically significant(P<0.05).The survival rates in the observation group at 3 months,6 months,and 1 year after treatment were 100.00%,98.21%,and 94.64%,which were significantly higher than 92.86%,87.50%,and 80.36%in the control group,and the differences were statistically significant(P<0.05).Conclusion Erlotinib targeted therapy can improve the immune function and prolong the survival time of patients with non-small cell lung cancer,which is worth promoting.

关 键 词：非小细胞肺癌 埃罗替尼 靶向治疗 免疫功能 生存时间 

分 类 号：R734.2[医药卫生—肿瘤]